Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

21 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Galapagos Articles

AbbVie to pay $50 million to expand GLPG0634 deal with Galapagos to Crohn's disease

17 May 2013

Roche pulls out of fibrosis alliance with Galapagos

11 March 2013

News briefs from Alimera on Iluvien and Xencor on Xtend; Galapagos milestone and acquisition

17 January 2013

Galapagos unit in CNS discovery deal with Ono Pharma

3 September 2012

AstraZeneca in deal with Galapagos; view on Seroquel law suit

15 March 2012

Galapagos leaps on $1.35 billion RA drug deal with Abbott Labs

1 March 2012

GSK exercises option for Galapagos drug candidates

21 February 2012

Unexpectedly strong data for Galapagos rheumatoid arthritis drug candidate

24 November 2011

Servier and Galapagos in 260 million-euro oncology deal

4 October 2011

Galapagos units extend drug discovery collaboration with Genentech

19 August 2011

Merck & Co posts fourth-quarter 2010 loss of $531 million as a result of charges; drops alliance with Galapagos

4 February 2011

Galapagos in deal with Johnson & Johnson unit for oncology target in 33.5 million-euro deal; US FDA delays J&J’s tapentadol ER

5 October 2010

GlaxoSmithKline sells Croatian research center to Galapagos, names new CFO and enters supply deal with Lonza; EMEA update on Avandia and Pandemrix

9 September 2010

Servier in 300-millon-euro deal with Galapagos to target osteoarthritis

5 July 2010

Showing 1-14 of 14 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS